<span item_type="fundamental" item_id="740cfe8e0447a2da5e09a454d37cd874" counter_id="ST/US/JACS" env="prod"></span><span item_type="announcement" item_id="513946205568566145" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 0.08.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and does not expect to generate operating revenues until after the completion of a Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Operational costs for the three months ended March 31, 2025, were $206,321.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li><li>Net income for the same period was $2,227,401, primarily due to interest earned on marketable securities held in the Trust Account amounting to $2,433,722.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the three months ended March 31, 2025, was - $193,398.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li><li>Cash at the end of the period was $755,968, down from $949,366 at the beginning of the period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Investments held in the Trust Account increased to $235,292,200 as of March 31, 2025, from $232,858,478 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company intends to focus its search for a target business in the healthcare services and healthcare technology sector.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li><li>The company has until December 11, 2026, to complete a Business Combination, failing which it will redeem 100% of the outstanding Public Shares and liquidate.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li></ul><h3>Priority</h3><ul><li>The company plans to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform due diligence, and complete a Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2039058/000121390025041127/ea0241126-10q_jackson2.htm"></span></li></ul>

Jackson Acquisition Co II | 10-Q: FY2025 Q1 EPS: USD 0.08